Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma
- 29 March 2010
- journal article
- Published by Wiley in BJU International
- Vol. 106 (10) , 1502-1507
Abstract
Study Type – Therapy (case series) Level of Evidence 4 OBJECTIVES: To report the heterogeneity in the treatment of patients with cT1 urothelial carcinoma by different surgeons, and to report outcomes in patients with and without bacillus Calmette‐Guérin (BCG) treatment. PATIENTS AND METHODS: We retrospectively reviewed 396 patients who had undergone a re‐staging transurethral resection (TUR) for cT1 bladder cancer. We assessed both differences in the treatment by surgeon, and the association of early treatment with BCG with recurrence, progression and bladder cancer‐specific death. RESULTS: Muscle was captured in the re‐staging TUR specimen in a median of 76% of patients (range 50–94 when stratified by surgeon). On multivariable analysis there was significant heterogeneity among surgeons in the use of early cystectomy ( P < 0.001), deferred cystectomy ( P < 0.001), and BCG ( P = 0.014). However, there was no significant heterogeneity between surgeons in clinical outcome for recurrence ( P = 0.9) and overall survival ( P = 0.3). Among 288 patients placed on surveillance, the 5‐year probability (95% confidence interval) of freedom from recurrence was 45 (36–54)% for those receiving and 54 (44–62)% for those not receiving early BCG. On multivariable analysis, early BCG was not significantly associated with recurrence ( P = 0.14). The cumulative incidence of progression was ≈10% for both groups, and the cumulative incidence of bladder cancer‐specific death was ≈7% for both groups. The cumulative incidence of deferred cystectomy before progression was 14% for those receiving and 15% for those not receiving early BCG. CONCLUSIONS: There is a significant variability among surgeons in the management of patients with T1 disease. The similar outcome for the BCG‐treated and ‐untreated patients in our study is most likely confounded by patient selection.Keywords
This publication has 12 references indexed in Scilit:
- Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1 Bladder CancerEuropean Urology, 2009
- EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the BladderEuropean Urology, 2008
- Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 UpdateJournal of Urology, 2007
- Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long‐term analysis of 132 patientsInternational Journal of Urology, 2007
- Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder CancerJournal of Urology, 2007
- Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trialsUrology, 2006
- A Retrospective Analysis of 153 Patients Treated With or Without Intravesical Bacillus Calmette-Guerin for Primary Stage T1 Grade 3 Bladder Cancer: Recurrence, Progression and SurvivalJournal of Urology, 2003
- Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical TrialsJournal of Urology, 2002
- Variability in the Recurrence Rate at First Follow-up Cystoscopy after TUR in Stage Ta T1 Transitional Cell Carcinoma of the Bladder: A Combined Analysis of Seven EORTC StudiesEuropean Urology, 2002
- Letter to the editorHuman Pathology, 1999